From q3 2013 to q3 2014 the cash increased by 100K. That doesnt sound like much but during that period they had legal fees for the lawsuit that must have been several 100K I would think. That expense is now gone I believe.
"Cash at the end of the third quarter totaled $.70 million, up 17% from $.60 million at the end of the third quarter 2013"
The revs you state includeed Bio which was sold sept 29th. CBAI going forward only contains numbers from Cord:
When reviewing the Results of Operations for both the Three and Nine Months Ended September 30, 2014, the results are on a consolidated basis and continuing operations which reflect our business going forward will be referenced as "Cord". A full breakdown of consolidated financial results, discontinued operations and continuing operations can be found in our 10-Q.
Results of Operations for the Three-Months Ended September 30, 2014
For the three months ended September 30, 2014, total revenue decreased to approximately $1.20 million from $1.49 million, a decrease over the same period of 2013 related to the sale of Bio.
For Cord, there was an increase in its total revenues from $0.96 million to $1.20 million, or a 25% increase over the prior comparative three month period. Processing fees, recurring storage fees and tissue related product sales increased 5%, 5% and 187% respectively over the prior comparative three month period.
CBAI Cord Tissue Sales Exploding as far as I can tell.
I have been looking thru CBAI PR's and found some interesting things. Near the end of q2 2014 june 25th CBAI announces a new product service offering for the isolation and expansion of mesenchymal stem cells. they call it CorCell IsoCell™. When I did a google search of "the isolation and expansion of mesenchymal stem cells" CorCell is the 1st company that comes up other than research stuff and paid advertizing.
During q2 2014 Cord Tissue sales were up 20%. Then the next q3 2014 the 1st full quarter that this new tissue offering was available, Tissue related sales were up 187% and total revenues up 25%! Id bet most of that 25% growth is Tissue products.
Will the rev sales continue to increase? I believe they will as the CEO said this on the last 10q
It has also allowed us to focus on the areas of profitable growth in our domestic Cord operations from enrollment fees, recurring storage revenue across multiple products and tissue related product sales where we saw an increase of over 180% in the third quarter from the year ago period. We believe we have positioned the company to have a significantly broader product base diversifying our revenue. We have also been able to ramp our sales and marketing efforts to support this product base, and are excited about the opportunities this has already culminated in for the company which we look forward to updating the investment community on as they progress."
